| Popis: |
Providing safe and effective pharmacotherapy to geriatric patients with rheumatological disorders is challenging. Multidisciplinary care involving rheumatologists, primary care physicians and other specialties can optimize benefit and reduce adverse outcomes. Oral disease-modifying antirheumatic drugs, including methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide, and the small molecule inhibitors tofacitinib and apremilast have distinctive monitoring requirements and specific adverse reaction profiles. This article provides clinically relevant pearls for use of these interventions in older patients. |
